Beone Medicines (ONC) Fundamental Analysis: Revenue, Earnings & Valuation

3.07 / 10

Netural

The company exhibits weak fundamental metrics (3.1/10). Strengths observed in Fixed assets turnover ratio and Cost of sales ratio (%), despite concerns regarding Diluted earnings per share (YoY growth rate %) and PB-ROE. Lead to constrained appraisal.

Analysis Checks(8/10)

Total operating revenue (YoY growth rate %)

Value40.23

Score2/3

Weight2.50%

1M Return0.32%

Inventory turnover ratio

Value1.21

Score3/3

Weight-4.27%

1M Return-0.51%

PB-ROE

Value2.94

Score0/3

Weight34.05%

1M Return3.62%

Fixed assets turnover ratio

Value3.05

Score2/3

Weight-5.93%

1M Return-0.77%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.97

Score2/3

Weight-8.35%

1M Return-1.10%

Diluted earnings per share (YoY growth rate %)

Value140.43

Score0/3

Weight-30.07%

1M Return-4.08%

Operating revenue (YoY growth rate %)

Value40.23

Score2/3

Weight2.20%

1M Return0.28%

Cost of sales ratio (%)

Value12.51

Score3/3

Weight7.19%

1M Return0.82%

Asset-MV

Value-0.55

Score2/3

Weight107.37%

1M Return10.36%

Net profit / Total profit (%)

Value68.83

Score2/3

Weight-4.69%

1M Return-0.60%

Is ONC fundamentally strong?

ONC scores 3.07/10 on fundamentals and holds a Fair valuation at present. Backed by its 7.46% ROE, 5.37% net margin, 114.82 P/E ratio, 7.55 P/B ratio, and 142.55% earnings growth, these metrics solidify its Netural investment rating.